Amarin Corporation Plc

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amarin reports robust Q4 earnings, eyes global expansion opportunities

Amarin's Q4 2022 earnings call highlighted strong financial performance, successful global expansion efforts, and a focus on cash preservation and talent acquisition. The company's UK launch milestones and international progress position it well for future growth.

Amarin reports Q1 revenue growth amidst pricing challenges and opportunities

Amarin focuses on revenue growth and cost-saving initiatives to drive operational efficiency and profitability.
The company's strong cash position provides stability for future growth initiatives and strategic investments.
Challenges include pricing pressure from generics and the need to balance expenses with revenue growth.
Opportunities lie in expanding prescription growth, product portfolio, and exploring strategic partnerships.

Amarin Corporation Plc reports robust Q3 earnings and strategic growth plans

Amarin Corporation Plc's Q3 2023 earnings call showcased strong financial performance, operational decisions driving positive cash flow, and a focus on maximizing shareholder value. While challenges in the European market and uncertainties around stock price were noted, opportunities for growth in global markets and strategic initiatives offer potential for future success.

Amarin reports solid Q4 revenue growth and eyes global expansion

Amarin's Q4 2023 performance reflects revenue growth and ongoing investment in strategic initiatives.
The company's strong financial position and operational momentum in key markets position it well for future growth.
Challenges around market dynamics, expenses management, and competition require strategic focus for sustained success.

Amarin reports stable Q1 earnings, focuses on European growth opportunities

Amarin Corporation's Q1 2024 earnings call highlighted solid financial performance, successful IP defense in Europe, and positive clinical outcomes for its key products. While facing challenges in the U.S. market due to generic competition, the company maintains profitability and a strong cash position. Opportunities lie in shareholder value enhancement and continued growth in Europe.

Amarin reports stable revenue but faces generic competition challenges

Amarin's Q2 2024 performance reflects revenue decline in the U.S. due to generic competition but improved net income from expense reductions. The company's strengths lie in the success of Vascepa/VAZKEPA and maintaining market share. Challenges include adapting to changing market dynamics, while opportunities exist in global expansion and strategic initiatives.

Amarin reports Q3 revenue of $42.3M, focuses on global expansion

Amarin's Q3 2024 performance reflects a mixed financial outcome with total net revenue of $42.3M and a GAAP net loss of $25.1M, impacted by challenges in the U.S. generic market.
Despite facing pricing pressures and cost reduction efforts, the company maintains a stable cash position of $306M and remains focused on global expansion.
The strengths lie in the proven science and support for VASCEPA/VAZKEPA, with opportunities to address the unmet need in reducing cardiovascular disease globally.
Challenges include navigating market dynamics and maintaining profitability amidst pricing pressures, while upcoming events signal proactive engagement for long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

DUBLIN, Ireland and BRIDGEWATER, N.J., July  21, 2020  (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company's second quarter 2020 financial results and provide an operational update on Tuesday, August 4, 2020, at 7:30 a.m. ET. The conference call will follow the anticipated release of the company's financial results earlier that day.

Amarin to Report Second Quarter 2020 Results and Host Conference Call on August 4, 2020

The pharma stock collapsed on the threat of generic competition for a drug that launched in December 2019, but the move may have been a bit of an overreaction.

Here's Why Amarin Tumbled 67.7% in the First Half of 2020

Super League Gaming Inc

Their share prices are predicted to bounce back strongly.

Analysts Recommend Catching These 2 Falling Knives

In the latest trading session, Amarin (AMRN) closed at $7.03, marking a +1.59% move from the previous day.

Amarin (AMRN) Outpaces Stock Market Gains: What You Should Know

Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

Implied Volatility Surging for Amarin (AMRN) Stock Options

In the latest trading session, Amarin (AMRN) closed at $6.92, marking a +0.58% move from the previous day.

Amarin (AMRN) Gains But Lags Market: What You Should Know

Amarin Corporation plc (NASDAQ: AMRN) announced late Tuesday a settlement agreement with Apotex for resolving a patent lawsuit regarding a generic version of Amarin's drug Vascepa.

Amarin Analysts Say Vascepa Patent Settlement Not A Stock Mover, With 'Little Readthrough For Pending Patent Appeal'

DUBLIN, Ireland and BRIDGEWATER, N.J., June  16, 2020  (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today a settlement agreement with Apotex Inc. (Apotex) that resolves patent litigation that would have resulted from the previously disclosed abbreviated new drug application (ANDA) filed by Apotex with U.S. Food and Drug Administration (FDA) and amended in May 2020 seeking approval of a generic form of VASCEPA® (icosapent ethyl) capsules based on the MARINE study.

Amarin Announces Patent Litigation Settlement Agreement with Apotex Inc.

Is it time to buy Amarin Corp. (NASDAQ: AMRN)?

Why Some Analysts Remain Bullish on Amarin Stock

Primary composite first and total major adverse cardiovascular event (MACE) reductions of 23% each shown with VASCEPA in prespecified tertiary and post hoc exploratory analyses of the subgroup of people with diabetes

VASCEPA® (icosapent ethyl) Shows Significant Cardiovascular Risk Reduction in People with Diabetes in Prespecified and Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study

Amarin (AMRN) closed the most recent trading day at $6.59, moving -1.35% from the previous trading session.

Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know

Last week, Amarin Corp. PLC (NASDAQ: AMRN) filed its proxy statement with the U.S.

What Amarin Stock Investors Will Hear at the Annual Meeting

Amarin: Dr. Bhatt's Important New Report Suggests Fresh Angle To The Appeal

On Wednesday, Oppenheimer analysts reiterated their Hold rating for Amarin (NASDAQ: AMRN).

Amarin Stock in a Holding Pattern

As Amarin Corp. (NASDAQ: AMRN) awaits a patent trial that could make or break the business, it continues forging ahead.

Will New Marketing Push Pump Amarin Stock?

In recent news, Amarin's legal brief has been filed, and generic Vascepa has been FDA-approved.

Amarin: Some Investment Strategies For 2020

Significant Opportunity Seen as Patient Visits Resume to Emphasize VASCEPA as the First and Only Drug Approved for Its Current Cardiovascular Risk Reduction Indication Significant Opportunity Seen as Patient Visits Resume to Emphasize VASCEPA as the First and Only Drug Approved for Its Current Cardiovascular Risk Reduction Indication

Amarin Plans to Increase VASCEPA® (icosapent ethyl) Promotion and Education

In late September of 2018, Dublin-based Amarin Corp. (NASDAQ: AMRN) first reported positive results from clinical trials of its product Vascepa.

How Court Ruling, COVID-19 Use Could Close 2020 Amarin Stock Saga

Researchers learn more about COVID-19 every day. Only identified in December 2019, the novel coronavirus still keeps many secrets while it wreaks havoc on the planet.

Potential COVID-19 Treatment Could Help Amarin Stock

The arrival of a generic version of Vascepa will be bad news for the company.

FDA Approves Generic Version of Amarin's Blockbuster Fish Oil Capsules

Amarin Corporation plc (NASDAQ: AMRN) shares, which were higher in after-hours trading Thursday following the company's announcement regarding a third-party pilot trial of its Vascepa in COVID-19, were giving back the gains Friday.

Generic Threat To Amarin's Vascepa Overrides Positive Sentiment On Coronavirus Announcement

Amarin Corporation PLC (NASDAQ: AMRN) has been fighting an uphill battle since the end of March.

Amarin Stock’s Potential Unhampered by Generic Approval

U.S. patents protecting the only revenue source for this biotech company were recently invalidated, and the dust won't settle anytime soon.

1 Biotech Stock to Avoid at All Costs

Amarin's Legal Appeal Part 3 - The Second Argument And Some Words Of Caution

DUBLIN, Ireland and BRIDGEWATER, N.J., May  21, 2020  (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced support for a clinical trial to investigate the effects of icosapent ethyl (IPE) (VASCEPA®) on inflammatory biomarkers and other patient outcomes in individuals with COVID-19. The trial is sponsored by the Canadian Medical and Surgical Knowledge Translation Research Group and is being led by Dr. Subodh Verma MD, FRCSC, FAHA, PhD, cardiac surgeon‐scientist at St. Michael's Hospital in Toronto, and professor at the University of Toronto, and Dr. Deepak L. Bhatt MD, MPH, Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital and Professor, Harvard Medical School. The trial primary endpoint is the effect of VASCEPA versus usual care on high-sensitivity C-reactive protein levels from baseline to 14 days in adults with a COVID-19-positive diagnosis. The clinical study design also includes other endpoints that assess rates and severity of COVID-19 infection in this high-risk group.

News for Amarin Corporation Plc Stock (AMRN)